Details of the Drug

General Information of Drug (ID: DM6KXAU)

Drug Name

Dexpramipexole

Synonyms

Dexpramipexole; 104632-28-2; (R)-PRAMIPEXOLE; (R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine; R-(+)-Pramipexole; (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; WI638GUS96; KNS-760704; (6R)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; Dexpramipexole [USAN:INN]; UNII-WI638GUS96; (R)-Pramipexole;R-(+)-Pramipexole;KNS-760704; Dexpramipexole (USAN/INN); DEXPRAMIPEXOLE [INN]; SCHEMBL74780; DEXPRAMIPEXOLE [USAN]; MLS006011813; CHEMBL249420; DEXPRAMIPEXOLE [WHO-DD]; DTXSID50146624; FASDKYOPVNHBLU-SSDOTTSWSA-N; BCP12512; 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6R)-; BDBM50568780; HY-17355B; AKOS005555111; CS-1196; DB15130; AC-36724; AS-56557; SMR004703492; D09886; EN300-123062; F19514; Q5268345; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine; (R)-4,5,6,7-TETRAHYDRO-6-(PROPYLAMINO)-BENZOTHIAZOLE-2-AMINE; 2,6-BENZOTHIAZOLEDIAMINE, 4,5,6,7-TETRAHYDRO-N6-PROPYL-, (R)-

Indication

Disease Entry	ICD 11	Status	REF
Eosinophilic asthma	CB02.0	Phase 3	[1]
Hypereosinophilic syndrome	2A20.3	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C10H17N3S
Canonical SMILES: CCCNC1CCC2=C(C1)SC(=N2)N
InChI: InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m1/s1
InChIKey: FASDKYOPVNHBLU-SSDOTTSWSA-N

Cross-matching ID

PubChem CID: 59868
TTD ID: DP2UR8

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Inhibitor	[3]
Interleukin-4 (IL4)	TTLGTKB	IL4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05763121) A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT02101138) An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome. U.S.National Institutes of Health.
3	Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.